Exon Skipping in a Dysf-Missense Mutant Mouse Model
Limb girdle muscular dystrophy 2B (LGMD2B) is without treatment and caused by mutations in the dysferlin gene (DYSF). One-third is missense mutations leading to dysferlin aggregation and amyloid formation, in addition to defects in sarcolemmal repair and progressive muscle wasting. Dysferlin-null mo...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2018-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_5d1d3497ef3d4ad2a0b0bfd742e30f43 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Jakub Malcher |e author |
| 700 | 1 | 0 | |a Leonie Heidt |e author |
| 700 | 1 | 0 | |a Aurélie Goyenvalle |e author |
| 700 | 1 | 0 | |a Helena Escobar |e author |
| 700 | 1 | 0 | |a Andreas Marg |e author |
| 700 | 1 | 0 | |a Cyriaque Beley |e author |
| 700 | 1 | 0 | |a Rachid Benchaouir |e author |
| 700 | 1 | 0 | |a Michael Bader |e author |
| 700 | 1 | 0 | |a Simone Spuler |e author |
| 700 | 1 | 0 | |a Luis García |e author |
| 700 | 1 | 0 | |a Verena Schöwel |e author |
| 245 | 0 | 0 | |a Exon Skipping in a Dysf-Missense Mutant Mouse Model |
| 260 | |b Elsevier, |c 2018-12-01T00:00:00Z. | ||
| 500 | |a 2162-2531 | ||
| 500 | |a 10.1016/j.omtn.2018.08.013 | ||
| 520 | |a Limb girdle muscular dystrophy 2B (LGMD2B) is without treatment and caused by mutations in the dysferlin gene (DYSF). One-third is missense mutations leading to dysferlin aggregation and amyloid formation, in addition to defects in sarcolemmal repair and progressive muscle wasting. Dysferlin-null mouse models do not allow study of the consequences of missense mutations. We generated a new mouse model (MMex38) carrying a missense mutation in exon 38 in analogy to a clinically relevant human DYSF variant (DYSF p.Leu1341Pro). The targeted mutation induces all characteristics of missense mutant dysferlinopathy, including a progressive dystrophic pattern, amyloid formation, and defects in membrane repair. We chose U7 small nuclear RNA (snRNA)-based splice switching to demonstrate a possible exon-skipping strategy in this new animal model. We show that Dysf exons 37 and 38 can successfully be skipped in vivo. Overall, the MMex38 mouse model provides an ideal tool for preclinical development of treatment strategies for dysferlinopathy. Keywords: dysferlin, dysferlinopathy, mouse model, MMex38, exon skipping, U7 snRNA, AAV | ||
| 546 | |a EN | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Molecular Therapy: Nucleic Acids, Vol 13, Iss , Pp 198-207 (2018) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2162253118302257 | |
| 787 | 0 | |n https://doaj.org/toc/2162-2531 | |
| 856 | 4 | 1 | |u https://doaj.org/article/5d1d3497ef3d4ad2a0b0bfd742e30f43 |z Connect to this object online. |